But it is also approved by the Food and Drug Administration (FDA) to lower the risk of cardiovascular events in adults with heart disease who have excess weight or obesity, and to treat adults with an advanced liver disease known as metabolic-associated steatohepatitis (MASH)
Ethics declarations Conflict of interest Mette JF Nielsen, Helene H Hansen Duus, Katrine Kirkeby, Britt W Lauenborg, Benjamin Low and Louise Witten are employees and stockholders of Novo Nordisk A/S
10.1080/09168451.2015.1052767 73 SorrentiS.BaldiniE.PironiD.LauroA.DoraziV.TartagliaF.et al (2021)
10.1038/s41576-023-00580-2 170 VaradiM.AnyangoS.DeshpandeM.NairS.NatassiaC.YordanovaG.et al (2021)
Together, we can explore the best treatment options tailored to your needs and embark on a journey towards a healthier, happier life
Notably, GLP-1RA characterized by signaling bias favoring cAMP production over beta-arrestin recruitment has been regarded as more effective in controlling glucose and body weight in experimental mice compared to unbiased agonists [43, 44]